Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A

Supharat Jariyakosol,1,2 Lita Uthaithammarat,1,2 Nattakarn Chatwichaikul,1,2 Ngamjit Kasetsuwan,1– 3 Yuda Chongpison4 1Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Ophthalmology Department, King Chulalongkorn Memorial Hospital, Thai Red Cr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jariyakosol S, Uthaithammarat L, Chatwichaikul N, Kasetsuwan N, Chongpison Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	hemifacial spasm botulinum toxin dry eye fluorescein clearance test prevalence of dry eye Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/c904971fa3b4447488e4a92722ab4dbc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c904971fa3b4447488e4a92722ab4dbc
record_format	dspace
spelling	oai:doaj.org-article:c904971fa3b4447488e4a92722ab4dbc2021-12-02T16:47:07ZDry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A1177-5483https://doaj.org/article/c904971fa3b4447488e4a92722ab4dbc2021-04-01T00:00:00Zhttps://www.dovepress.com/dry-eye-disease-in-hemifacial-spasm-patients-treated-with-botulinum-to-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Supharat Jariyakosol,1,2 Lita Uthaithammarat,1,2 Nattakarn Chatwichaikul,1,2 Ngamjit Kasetsuwan,1– 3 Yuda Chongpison4 1Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Ophthalmology Department, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 3Center of Excellence for Cornea and Stem Cell Transplantation, Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 4Biostatistic Excellence Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandCorrespondence: Supharat Jariyakosol 1873 Rama IV Road, Pathumwan, Bangkok, 10330, ThailandTel +662-2564142Email jsupharat@gmail.comPurpose: To assess the impact of botulinum toxin type A (BTX-A) on signs and symptoms of dry eye (DE) in affected eye of hemifacial spasm (HFS) patients and to compare the prevalence of DE between affected and non-affected eye in HFS patients.Patients and Methods: This prospective study included participants with unilateral HFS, who received BTX-A injection as a treatment. The eyes ipsilateral to the spasm side were used as studied eyes and the contralateral eyes were used as controls. The Ocular Surface Disease Index (OSDI) score, tear break-up time (TBUT), corneal fluorescein staining, and Schirmer I test were measured at baseline, 1 and 3 months after BTX-A injection. Fluorescein clearance test (FCT) was evaluated at baseline and at 1 month after BTX-A injection.Results: Thirty-one participants (6 males and 25 females; mean age 61± 10 years) were included. The prevalence of DE according to the Asia Dry Eye Society was not significantly different between affected (37.93%) and non-affected eyes (27.6%); P=0.083. At baseline, there was no significant difference in TBUT, Schirmer test, basal tear secretion, presence of delayed tear clearance, and presence of reflex tear secretion between affected and non-affected eyes, while significant difference in Oxford scheme grade was observed (P=0.031). OSDI score, TBUT, Oxford scheme grade, and Schirmer test at 1 month (P=0.817, 0.796, 0.534, 0.556), and 3 months (P=0.803, 0.904, 0.936, 0.684) after BTX-A injection did not significantly change from baseline in affected eyes. FCT results were not significantly different between baseline and at 1-month follow-up in both groups. All findings were corresponding in both naïve and long-term botulinum toxin injection groups.Conclusion: We found no significant effect of BTX-A on signs and symptoms of DE in patients with HFS. Moreover, there was no significant association between HFS and DE. However, we found significant corneal surface damage in the affected eyes, which emphasized importance of ocular surface evaluation and prompt treatment in HFS patients.Keywords: hemifacial spasm, botulinum toxin, dry eye, fluorescein clearance test, prevalence of dry eyeJariyakosol SUthaithammarat LChatwichaikul NKasetsuwan NChongpison YDove Medical Pressarticlehemifacial spasmbotulinum toxindry eyefluorescein clearance testprevalence of dry eyeOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 1775-1782 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hemifacial spasm botulinum toxin dry eye fluorescein clearance test prevalence of dry eye Ophthalmology RE1-994
spellingShingle	hemifacial spasm botulinum toxin dry eye fluorescein clearance test prevalence of dry eye Ophthalmology RE1-994 Jariyakosol S Uthaithammarat L Chatwichaikul N Kasetsuwan N Chongpison Y Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
description	Supharat Jariyakosol,1,2 Lita Uthaithammarat,1,2 Nattakarn Chatwichaikul,1,2 Ngamjit Kasetsuwan,1– 3 Yuda Chongpison4 1Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 2Ophthalmology Department, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 3Center of Excellence for Cornea and Stem Cell Transplantation, Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 4Biostatistic Excellence Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandCorrespondence: Supharat Jariyakosol 1873 Rama IV Road, Pathumwan, Bangkok, 10330, ThailandTel +662-2564142Email jsupharat@gmail.comPurpose: To assess the impact of botulinum toxin type A (BTX-A) on signs and symptoms of dry eye (DE) in affected eye of hemifacial spasm (HFS) patients and to compare the prevalence of DE between affected and non-affected eye in HFS patients.Patients and Methods: This prospective study included participants with unilateral HFS, who received BTX-A injection as a treatment. The eyes ipsilateral to the spasm side were used as studied eyes and the contralateral eyes were used as controls. The Ocular Surface Disease Index (OSDI) score, tear break-up time (TBUT), corneal fluorescein staining, and Schirmer I test were measured at baseline, 1 and 3 months after BTX-A injection. Fluorescein clearance test (FCT) was evaluated at baseline and at 1 month after BTX-A injection.Results: Thirty-one participants (6 males and 25 females; mean age 61± 10 years) were included. The prevalence of DE according to the Asia Dry Eye Society was not significantly different between affected (37.93%) and non-affected eyes (27.6%); P=0.083. At baseline, there was no significant difference in TBUT, Schirmer test, basal tear secretion, presence of delayed tear clearance, and presence of reflex tear secretion between affected and non-affected eyes, while significant difference in Oxford scheme grade was observed (P=0.031). OSDI score, TBUT, Oxford scheme grade, and Schirmer test at 1 month (P=0.817, 0.796, 0.534, 0.556), and 3 months (P=0.803, 0.904, 0.936, 0.684) after BTX-A injection did not significantly change from baseline in affected eyes. FCT results were not significantly different between baseline and at 1-month follow-up in both groups. All findings were corresponding in both naïve and long-term botulinum toxin injection groups.Conclusion: We found no significant effect of BTX-A on signs and symptoms of DE in patients with HFS. Moreover, there was no significant association between HFS and DE. However, we found significant corneal surface damage in the affected eyes, which emphasized importance of ocular surface evaluation and prompt treatment in HFS patients.Keywords: hemifacial spasm, botulinum toxin, dry eye, fluorescein clearance test, prevalence of dry eye
format	article
author	Jariyakosol S Uthaithammarat L Chatwichaikul N Kasetsuwan N Chongpison Y
author_facet	Jariyakosol S Uthaithammarat L Chatwichaikul N Kasetsuwan N Chongpison Y
author_sort	Jariyakosol S
title	Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
title_short	Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
title_full	Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
title_fullStr	Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
title_full_unstemmed	Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A
title_sort	dry eye disease in hemifacial spasm patients treated with botulinum toxin type a
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/c904971fa3b4447488e4a92722ab4dbc
work_keys_str_mv	AT jariyakosols dryeyediseaseinhemifacialspasmpatientstreatedwithbotulinumtoxintypea AT uthaithammaratl dryeyediseaseinhemifacialspasmpatientstreatedwithbotulinumtoxintypea AT chatwichaikuln dryeyediseaseinhemifacialspasmpatientstreatedwithbotulinumtoxintypea AT kasetsuwann dryeyediseaseinhemifacialspasmpatientstreatedwithbotulinumtoxintypea AT chongpisony dryeyediseaseinhemifacialspasmpatientstreatedwithbotulinumtoxintypea
_version_	1718383421094363136

Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A

Ejemplares similares